On the Frontlines of Psoriasis

Host: Steve Jackson, PharmD


Psoriasis is more than a skin disease—it's a chronic, immune-mediated condition associated with significant psychiatric and psychosocial comorbidities, including depression, anxiety, and suicidal ideation. In this conversation with Dr. Steve Jackson, Dr. Margo Gkini shares practical strategies for screening and identifying mental health challenges in these patients. Dr. Gkini is a consultant dermatologist at Barts Health NHS Trust in London, as well as an Honorary Senior Lecturer at Queen Mary University.

Guest: Mio Nakamura, MD, MS

Host: Steve Jackson, PharmD


Psoriasis is more than a visible skin condition; it carries a profound psychological and emotional burden that can disrupt patients’ quality of life. In this conversation with Dr. Steve Jackson, Dr. Mio Nakamura shares practical insights on recognizing mental health impacts, assessing patient wellbeing beyond clinical severity, and integrating supportive resources into care. Dr. Nakamura is a Clinical Assistant Professor of Dermatology and Director of Clinical Research at the University of Michigan Medical School.

Host: Ryan Quigley

Guest: Jenny Murase, MD


Evolving insights into Th1-, Th2-, and Th17-driven inflammation are reshaping the diagnosis and management of patients presenting with mixed psoriasis subtypes. Ryan Quigley sits down with Dr. Jenny Murase to learn more about practical approaches to personalized treatment planning, common clinical pitfalls, and emerging strategies. Dr. Murase is the Founder and Chair of the American Academy of Dermatology Women's Health Expert Resource Group, as well as a Associate Clinical Professor at the UCSF Department of Dermatology and Deputy Chair of the Clinical Guidelines Committee for the American Academy of Dermatology.

Host: Ryan Quigley

Guest: Steven R. Feldman, MD, PhD


In psoriasis management, patient adherence is a persistent challenge, especially with topical therapies for mild involvement. Ryan Quigley sits down with Dr. Steve Feldman to explore evidence-based, real-world strategies to support these patients and promote long-term success. Dr. Feldman is a professor of dermatology, pathology, and public health sciences at Wake Forest University School of Medicine as well as a practicing dermatologist at Atrium Health Wake Forest Baptist in Winston-Salem, North Carolina.

Guest: Christopher Bunick, MD, PhD, FAAD

Host: Ryan Quigley


With high selectivity, durable response, and once-daily dosing, next-generation TYK2 inhibitors offer a promising oral option for patients with moderate-to-severe plaque psoriasis. Ryan Quigley sits down with Dr. Christopher Bunick, Associate Professor of Dermatology and Translational Biomedicine at Yale University School of Medicine, to learn more about how these agents may align with evolving patient preferences and expand options beyond injectables.